Development of experimental carbohydrate-conjugate vaccines composed of Streptococcus pneumoniae capsular polysaccharides and the universal helper T-lymphocyte epitope (PADRE). (Q47356311)

From Wikidata

Jump to navigation Jump to search

scientific article published in June 2004

Language	Label	Description	Also known as
English	Development of experimental carbohydrate-conjugate vaccines composed of Streptococcus pneumoniae capsular polysaccharides and the universal helper T-lymphocyte epitope (PADRE).	scientific article published in June 2004

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/15193395

Development of experimental carbohydrate-conjugate vaccines composed of Streptococcus pneumoniae capsular polysaccharides and the universal helper T-lymphocyte epitope (PADRE). (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/15193395

1 reference

based on heuristic

inferred from title

Streptococcus pneumoniae

1 reference

based on heuristic

inferred from title

6

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/15193395

Alessandro Sette

5

object named as

Alessandro Sette

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

author name string

Jeff Alexander

1

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/15193395

Marie-France del Guercio

2

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/15193395

Barbara Frame

3

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/15193395

Ajesh Maewal

4

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/15193395

Mark J Newman

7

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/15193395

language of work or name

0 references

publication date

1 June 2004

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/15193395

number of pages

6

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/15193395

22

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/15193395

19

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/15193395

2362-2367

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/15193395

Pneumococcal serotypes and their clinical relevance

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.061

7 January 2021

Incidence, capsular types, and antibiotic susceptibility of invasive Streptococcus pneumoniae in Sweden

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.061

7 January 2021

The role of opsonins in recovery from experimental pneumococcal pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.061

7 January 2021

Prevention of Pneumococcal Infection by Immunization with Capsular Polysaccharides of Streptococcus pneumoniae: Current Status of Polyvalent Vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.061

7 January 2021

Considerations for Formulating the Second-Generation Pneumococcal Capsular Polysaccharide Vaccine with Emphasis on the Cross-Reactive Types Within Groups

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.061

7 January 2021

Some observations on the pneumococcus and on the current status of pneumococcal disease and its prevention.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.061

7 January 2021

Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.061

7 January 2021

Inefficacy of pneumococcal vaccine in a high-risk population

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.061

7 January 2021

Magnitude, duration, quality, and function of pneumococcal vaccine responses in elderly adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.061

7 January 2021

Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.061

7 January 2021

Effect of conjugation methodology, carrier protein, and adjuvants on the immune response to Staphylococcus aureus capsular polysaccharides

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.061

7 January 2021

Polysaccharide-protein conjugates: a new generation of vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.061

7 January 2021

Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.061

7 January 2021

Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.061

7 January 2021

Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.061

7 January 2021

Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.061

7 January 2021

Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.061

7 January 2021

Development of a multi-specificity opsonophagocytic killing assay

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.061

7 January 2021

Current state of pneumococcal vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.061

7 January 2021

Immunization with a plasmid expressing pneumococcal surface protein A (PspA) can elicit protection against fatal infection with Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.061

7 January 2021

Species-specific binding of human secretory component to SpsA protein of Streptococcus pneumoniae via a hexapeptide motif

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.061

7 January 2021

Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.061

7 January 2021

Protection against Streptococcus pneumoniae elicited by immunization with pneumolysin and CbpA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.061

7 January 2021

The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.061

7 January 2021

Streptococcus pneumoniae polysaccharides conjugated to the outer membrane protein A from Klebsiella pneumoniae elicit protective antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.061

7 January 2021

Preparation of pneumococcal capsular polysaccharide-protein conjugate vaccines utilizing new fragmentation and conjugation technologies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.061

7 January 2021

Antibody responses to Haemophilus influenzae type b and diphtheria toxin induced by conjugates of oligosaccharides of the type b capsule with the nontoxic protein CRM197.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.061

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum antibody responses of juvenile and infant rhesus monkeys injected with Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-protein conjugates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.061

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2003.11.061

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/15193395

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/15193395

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47356311&oldid=1775339173"